drugset / Trial / NCT02346890
A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
RandomizedCrossoverOpen-labelTreatment
Summary
The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy volunteers taking Renvela.
Timeline
- Start
- 2013-04
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenapanor | Small molecule | 15 mg | — |
| Subject | sevelamer | Other / unclassified | 800 mg | — |
Indications
No indication recorded.